REDWOOD CITY, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (NASDAQ:GHDX) announced today a collaboration with Pfizer on the development of a genomic test to estimate the risk of recurrence following surgery for patients with Stage I-III renal carcinoma, clear cell type, that has not spread to other parts of the body. The clear cell type of renal carcinoma is the most common type of kidney cancer in adults, affecting an estimated 25,000 people each year in the United States. As part of the collaboration, the companies will apply the same molecular technology and clinical strategy Genomic Health used to develop its Oncotype DX(R) breast cancer test.
"Working together with Pfizer, we have the potential to address a serious unmet need," said Chu Chang, Genomic Health's Vice President of Business Development. "Many early-stage renal carcinoma patients experience a recurrence of their cancer, yet there is no accurate way to identify the most aggressive cancers in advance. This collaboration further expands our efforts to develop genomic tests for a variety of cancers that allow physicians and patients to individualize treatment decisions." About Genomic Health Genomic Health, Inc. (NASDAQ:GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test service, Oncotype DX(R), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com/.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the parties' ability to successfully develop a prognostic test for non-metastatic renal cell carcinoma. These risks and uncertainties include, but are not limited to: the risk that we may not obtain sufficient levels of reimbursement for any future tests we may develop; the risk of delay in developing new products; the risks and uncertainties associated with the regulation of our tests by FDA; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies and the other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the three-month period ended September 30, 2007. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners. DATASOURCE: Genomic Health, Inc.
CONTACT: Investors, Brad Cole, +1-650-569-2281, , or Media, Emily Faucette, +1-650-569-2824, , both of Genomic Health, Inc.
Web site: http://www.genomichealth.com/
|